ARDX

2.9902.29%
WC

William Charles A. Bertrand

Independent Director

Mr. William Charles A. Bertrand, also known as Bill, Jr., J.D., Esq. had been Chief Operating Officer at Adaptimmune Therapeutics plc since March 15, 2017 until November 14, 2025 and was its Secretary from October 1, 2025 to November 14, 2025 and was its Chief Compliance Officer since 2024 until November 14, 2025. Mr. Bertrand served as an Executive Vice President and General Counsel of Infinity Pharmaceuticals, Inc. from October 2015 to September 2, 2016 and also served as its Secretary until September 2, 2016. Mr. Bertrand joined Infinity Pharmaceuticals, Inc. in October 2015. He has extensive pharmaceutical experience and legal experience. He served as an Acting Chief Executive Officer of Salix Pharmaceuticals, Inc. from January 30, 2015 to April 1, 2015. Mr. Bertrand served as Senior Vice President of Legal, General Counsel and Corporate Secretary at Salix Pharmaceuticals Ltd. and Salix Pharmaceuticals, Inc since July 2013. He served as Acting Chief Operating Officer of Salix Pharmaceuticals; Inc. Mr. Bertrand joined Salix in July 2013. He served as Senior Vice President and General Manager at Salix Pharmaceuticals Ltd. and served as its Acting Chief Operating Officer from January 30, 2015 to April 1, 2015. Mr. Bertrand served as Secretary of Santarus, Inc. since January 02, 2014. He served as Executive Vice President of Legal Affairs of Medimmune Inc. (now MedImmune, LLC) since May 2008. Mr. Bertrand oversaw legal affairs, public affairs (including government affairs) and regulatory affairs for the Medimmune Inc. He served as General Counsel of MedImmune Ventures, Inc. He had responsibility for legal affairs, regulatory affairs, information services, corporate development and MedImmune Ventures, the wholly owned venture capital fund within the AstraZeneca Group. Mr. Bertrand served as Corporate Compliance Officer and General Counsel of Medimmune Inc. since November 2005 and served as its Corporate Secretary. He served as Senior Vice President of Legal Affairs of Medimmune Inc since November 2005. Mr. Bertrand was General Counsel at Medimmune since September 2003. He joined MedImmune, LLC in 2001 as Vice President, Legal Affairs and Corporate Compliance Officer from Pharmacia Corporation, where he held a variety of positions within the legal department, holding the title of including litigation counsel, senior corporate counsel and associate general counsel. In September 2007, his role expanded to oversee MedImmune's public affairs functions, including public relations, community relations and internal communications. Mr. Bertrand served in various legal positions at Pharmacia Corporation from 1997 to 2001. He served as Associate General Counsel for a life insurance company and a partner at Dickinson, Wright, Moon, Van Dusen & Freeman of Lansing, MI. He has admissions to Michigan, Wisconsin, U.S. District Court, Sixth Circuit Court of Appeals and the U.S. Supreme Court. Mr. Bertrand was responsible for global legal support for various Pharmacia products. His experience at Pharmacia also included advertising and promotion review, pricing issues, federal and state governmental legislative issues, contract negotiation and drafting and fraud and abuse prevention and training. He has been an Independent Director at Ardelyx, Inc. since October 2015. He had been a Director of TrustWave Holdings, Inc. since June 2011. He served as Director of Santarus, Inc. since January 02, 2014. He served as Director of Inotek Pharmaceuticals Corporation until May 2013. Mr. Bertrand served as a Director at BrainCells Inc. since March 2008. Mr. Bertrand was in private practice with a large Michigan-based law firm. He is also a member of the board of directors for the Tech Council of Maryland and the Montgomery County Business Roundtable for Education (MCBRE). He is a Partner at a law firm, taught classes at Johns Hopkins University and Seton Hall University School of Law and served on several boards of directors. He has lectured at Seton Hall University School of Law and is an adjunct professor for biotech strategy in Johns Hopkins University's Carey School of Business. He has a BS in Biology from Wayne State University and a Juris Doctorate degree from the University of Wisconsin-Madison.

Positions